At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Patients With Relapsed and Refractory Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Cobimetinib, Venetoclax, and 1 other intervention for Multiple Myeloma. Completed, enrolled 49 participants across 26 sites in 9 countries.
Detailed Summary
This open-label, randomized, multicenter, triple-arm Phase Ib/II study is designed to assess the efficacy, safety, tolerability, and pharmacokinetics of cobimetinib administered as a single agent (Arm A), cobimetinib plus venetoclax (Arm B), and cobimetinib plus venetoclax plus atezolizumab (Arm C) in participants with relapsed and refractory multiple myeloma. Two successive cohorts will evaluate the safety of cobimetinib plus venetoclax and that of cobimetinib plus venetoclax plus atezolizumab in the selected population during the safety run-in phase of the study. Once the dose levels have demonstrated acceptable safety during this phase, randomization will begin for all treatment arms (Arms A, B, and C).
Study Details
Timeline
Interventions
Cobimetinib will be administered as per the schedule specified in the respective arm.
Venetoclax will be administered as per the schedule specified in the respective arm.
Atezolizumab will be administered as per the schedule specified in the respective arm.